title: The rat Subcutaneous Air Sac model: a quantitative assay of antiangiogenesis in induced vessels.
abstract: A new in vivo experimental model--the Subcutaneous Air Sac (SAS) model-has recently been presented to replace a previous in vivo rabbit cornea assay where neovascularisation was induced by chemical injury of the cornea or by implantation of tumour cells intracorneally, a methodology which is believed to cause severe pain to the animals. In the SAS model, an air sac is induced by injection of air subcutaneously on the back of the animal. After 10-14 days the air sac appears as an almost transparent avascular membrane in which induction of new vessels can be studied. We present recent developments of this technique: In the SAS-tumour technique, vascular endothelial growth factor-producing tumour cells are inoculated subcutaneously directly on the membrane, and the formation of new vessels is measured 8 days later. In the SAS-pellet technique, slow-release pellets containing angiogenic factors, basic fibroblast growth factor or vascular endothelial growth factor are implanted on the subcutaneous membrane by a simple operation. The formation of new vessels is measured 10 days later. The ability of the SAS-tumour- and SAS-pellet techniques to detect an antiangiogenic effect of a systemically administered compound was investigated using the fumagillin analogue TNP-470 (o-chloroacetyl-carbamoyl)-fumagillol) as a positive control given subcutaneously for 7 and 9 days, respectively. At a dose of 10 mg TNP-470/kg/day the angiogenesis was reduced by approximately 70% in the SAS-tumour technique and by 40-60% in the SAS-pellet technique. The animals were unaffected by the SAS methodology. The SAS-tumour and SAS-pellet models are considered complementary and make use of simple and almost similar techniques which facilitate the evaluation.
authors.affiliation: Research and Development Department, Leo Pharmaceutical Products, Ballerup, Denmark.
authors.forename: J
authors.initials: J
authors.lastname: Lichtenberg
authors.forename: P J
authors.initials: PJ
authors.lastname: Hjarnaa
authors.forename: P E
authors.initials: PE
authors.lastname: Kristjansen
authors.forename: D
authors.initials: D
authors.lastname: Hansen
authors.forename: L
authors.initials: L
authors.lastname: Binderup
mesh_terms: D000400:Air Sacs / Q000502:physiology*; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D003510:Cyclohexanes; D003692:Delayed-Action Preparations; D004730:Endothelium, Vascular / Q000737:chemistry*; D005260:Female; D006133:Growth Substances / Q000502:physiology*; D007279:Injections, Subcutaneous; D009389:Neovascularization, Pathologic / Q000517:prevention & control*; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D011817:Rabbits; D051381:Rats; D017207:Rats, Sprague-Dawley; D012717:Sesquiterpenes / Q000494:pharmacology*